Exenatide News and Research

RSS

Exenatide (marketed as Byetta) is one of a new class of medications (incretin mimetics) approved for the treatment of diabetes mellitus type 2.

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

The advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control.

23 Jul 2024

New brain targets for GLP1-based obesity drugs may reduce weight without nausea

Researchers identified distinct hindbrain GLP1R neurons driving satiety and aversion, offering new targets for effective, side-effect-free obesity treatments.

14 Jul 2024

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond

A recent review in Diabetes Care evaluates the efficacy and safety of GLP-1 receptor agonists for type 2 diabetes and obesity, exploring their potential for new medical indications.

18 Jun 2024

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

The study reveals a significant increase in the usage of GLP-1 receptor agonists, particularly Ozempic and Trulicity, for weight management and Type 2 diabetes in the U.S. from 2014 to 2022. Amidst rapid growth and shortages, the paper calls for evidence-based decision-making to ensure stable medication supply and effective treatment.

17 Oct 2023

Revolutionizing type 2 diabetes treatment: personalized approach shows promise in matching patients with optimal glucose-lowering therapies

A personalized therapy selection algorithm for two diabetes type 2 (T2D) treatment drug classes.

10 Aug 2023

Injectable peptide used for type 2 diabetes shows potential for treating 'blinding' IIH headaches

Patients with 'blinding' headaches known as Idiopathic Intercranial Hypertension could be treated with an injectable peptide used for type 2 diabetes, a new trial has found.

13 Mar 2023

Gut hormone receptor polyagonists show promise for obesity and diabetes

A new paper in the Journal of Clinical Investigation describes drugs that could help lose weight and manage type 2 diabetes mellitus (T2DM).

6 Feb 2023

Machine learning and proteomics predict cardiovascular risk more accurately

An innovative proteomics-based model that predicts the risk of cardiovascular events with higher accuracy than current clinical models.

10 Apr 2022

Drug combo for Type 2 diabetes continues to stay effective after two years of treatment

Patients with Type 2 diabetes often take metformin as first-line therapy to help stabilize their blood glucose.

2 Nov 2020

Journal Of Parkinson's Disease announces recipients of first Parkinson Prize

The Journal of Parkinson's Disease and its publisher IOS Press are proud to announce the two articles that have won the first Parkinson Prize, recognizing these outstanding contributions to the advancement to Parkinson's disease research.

23 Jul 2020

Two newer types of diabetes medications show heart and kidney benefits

Two newer types of medications commonly used to treat type 2 diabetes are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease, according to research accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

31 Mar 2020

Diabetes drug could help with smoking cessation

Phillip Robinson has gone from 10 cigarettes a day to one or two every other day after enrolling in a smoking cessation clinical trial launched by researchers at The University of Texas Health Science Center at Houston

30 Apr 2019

Insulin resistance largely undetected in non-diabetic patients with Parkinson's disease

Almost two-thirds of non-diabetic patients with Parkinson's disease may be insulin resistant, despite having normal blood sugar, report scientists in the Journal of Parkinson's Disease.

3 Aug 2018

Exenatide treatment improves depression symptoms in PD patients

Non-motor symptoms of Parkinson's disease, such as depression, apathy, cognitive impairment, sleep disorders, and sensory symptoms, can have a greater impact on health-related quality of life than motor deficits.

1 Aug 2018

Study shows link between Parkinson’s and type 2 diabetes

A new study by UCL, University of Oxford and Queen Mary University of London researchers suggests that people with type 2 diabetes are 32% more likely to develop Parkinson’s disease than those without diabetes.

14 Jun 2018

Hacking 'drug trafficking' system could increase effectiveness of diabetes treatment

Making tiny changes to existing diabetes treatments can alter how they interact with cells, and potentially make the medicines more effective.

23 Apr 2018

Chemist finds how to control blood sugar without usual side effects

Chemist Robert Doyle in the College of Arts and Sciences at Syracuse University has figured out how to control glucose levels in the bloodstream without the usual side effects of nausea, vomiting or malaise.

11 Feb 2018

Diabetes patients least likely to follow medical advice regarding medication due to side effects

Diabetes patients who take the most commonly prescribed diabetes drug, metformin, are the least likely to follow medical advice regarding their medication due its side effects, a new article in the journal Diabetes, Obesity and Metabolism reports.

18 Dec 2017

Clinical trial to examine effectiveness of diabetes drug to slow or stop progression of Parkinson's

Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's.

8 Sep 2016

GLP-1 receptor agonist may benefit high-risk diabetes

Research shows that using a glucagon-like peptide-1 receptor agonist instead of a rapid-acting insulin analogue at mealtimes can reduce glycaemic variability in high-risk patients with Type 2 diabetes.

26 Apr 2016